Candel Therapeutics Quarterly Balance Sheet
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Candel Therapeutics financial position
As of Jun 30, 2026, Candel Therapeutics reported total assets of $208.1 million, up 96.4% from a year earlier against total liabilities of $82.0 million. Shareholders' equity stood at $126.1 million, or 60.6% of assets. The company held $201.6 million in cash and equivalents against $1.1 million of debt, a net cash position of $200.5 million.
The current ratio (current assets divided by current liabilities) was 16.09, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.01.
Summary generated from market data by MetaCap's automated system. Methodology
Candel Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 201.56M | 194.83M | 119.73M | 86.96M | 100.69M | 92.17M | 102.65M | 16.56M | 21.45M | 25.71M | 35.41M | 42.98M |
| Total Current Assets | 204.16M | 197.75M | 121.39M | 90.13M | 103.61M | 93.15M | 103.80M | 18.09M | 22.73M | 27.14M | 36.80M | 45.10M |
| Property, Plant & Equipment | 2.00M | 2.08M | 1.64M | 1.36M | 1.66M | 1.97M | 2.19M | 2.48M | 2.72M | 2.96M | 3.21M | 3.68M |
| Total Assets | 208.15M | 201.92M | 125.19M | 93.60M | 105.97M | 95.91M | 106.87M | 21.52M | 26.48M | 31.22M | 41.20M | 50.06M |
| Accounts Payable | 5.15M | 3.04M | 1.13M | 1.12M | 1.95M | 760.00K | 237.00K | 296.00K | 433.00K | 472.00K | 422.00K | 250.00K |
| Short-Term Debt | — | — | 0 | 4.22M | 6.70M | 9.17M | 9.89M | 9.85M | 9.81M | 9.77M | 8.89M | 6.10M |
| Total Current Liabilities | 12.69M | 7.05M | 9.00M | 10.93M | 14.71M | 20.07M | 37.53M | 15.27M | 14.00M | 13.54M | 14.18M | 10.33M |
| Long-Term Debt | 1.09M | 1.05M | 1.01M | 973.00K | 939.00K | 904.00K | 1.73M | 4.22M | 6.71M | 9.17M | 11.63M | 14.34M |
| Total Liabilities | 82.02M | 63.89M | 73.27M | 13.47M | 15.76M | 21.23M | 40.54M | 36.77M | 36.46M | 25.24M | 28.46M | 27.04M |
| Shareholders' Equity | 126.13M | 138.03M | 51.92M | 80.12M | 90.21M | 74.67M | 66.33M | -15.26M | -9.97M | 5.98M | 12.74M | 23.02M |
| Retained Earnings | -278.15M | -239.25M | -230.39M | -200.89M | -189.62M | -184.83M | -192.21M | -178.13M | -167.49M | -145.25M | -137.03M | -125.93M |
| Total Debt | 1.09M | 1.05M | 1.01M | 5.20M | 7.64M | 10.08M | 11.63M | 14.08M | 16.51M | 18.94M | 20.52M | 20.44M |
| Net Cash (Debt) | 200.48M | 193.79M | 118.72M | 81.77M | 93.04M | 82.09M | 91.03M | 2.48M | 4.94M | 6.77M | 14.89M | 22.54M |
| Shares Outstanding | 76.12M | 73.26M | 54.90M | 54.90M | 54.89M | 49.25M | 46.81M | 32.13M | 31.06M | 29.35M | 29.09M | 28.92M |
This table shows 12 quarterly periods of Candel Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow CADL's reporting calendar. What is a balance sheet?